Arginine butyrate

Drug Profile

Arginine butyrate

Alternative Names: HQK-1004

Latest Information Update: 06 Aug 2015

Price : $50

At a glance

  • Originator Boston University
  • Developer Boston University; HemaQuest Pharmaceuticals
  • Class Basic amino acids; Butyrates; Diamino amino acids; Essential amino acids; Small molecules
  • Mechanism of Action Thymidine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cancer; Epstein-Barr virus infections; Sickle cell anaemia; Thalassaemia

Most Recent Events

  • 05 Jan 2011 Arginine butyrate is available for licensing as of 05 Jan 2011. http://www.hemaquest.com
  • 05 Nov 2010 HemaQuest Pharmaceuticals terminates a phase II trial [NCT00992732] in EBV-positive lymphoid malignancies in USA
  • 06 Jul 2010 HemaQuest Pharmaceuticals terminates a phase II trial [NCT00917826] in EBV-positive lymphoid malignancies in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top